Maximum weight loss — I want the strongest possible resultsTirzepatide averages 22% body weight loss vs 15% for semaglutide
Proven, established option — I want the most clinical data behind my choiceSemaglutide has 8+ years of post-market data and the SELECT cardiovascular trial
Most affordable effective optionCompounded semaglutide starts ~$50/month cheaper than tirzepatide
Not sure yet — let the quiz recommendWe'll assess your full profile
Yes — type 2 diabetes diagnosisTirzepatide lowers HbA1c more (2.0% vs 1.5%) and produces more weight loss in diabetic patients
Yes — prediabetes or insulin resistanceTirzepatide's GIP component specifically targets insulin resistance — stronger clinical rationale here
Yes — PCOS (often involves insulin resistance)Tirzepatide's dual mechanism addresses the metabolic driver of PCOS more directly
No — none of the aboveWithout insulin resistance, semaglutide's single mechanism is often sufficient and more affordable
Yes — I plateaued on semaglutide and stopped losingSwitching to tirzepatide frequently restarts progress — this is the primary clinical use case for the switch
Yes — I stopped due to side effectsTirzepatide has a similar side effect profile. Consider whether slower titration would have helped.
Yes — I'm currently on semaglutide and it's workingIf results are good, no reason to switch. Stay the course.
No — this would be my first GLP-1 medicationEither is appropriate as a first medication; your other answers will guide the recommendation
Yes — heart disease, prior heart attack, or strokeSemaglutide's SELECT trial showed 20% reduction in major cardiovascular events — the strongest cardiovascular evidence of any GLP-1
High cardiovascular risk (family history, high blood pressure, smoking)Semaglutide's cardiovascular data is more established — relevant for high-risk patients
No significant cardiovascular historyBoth medications are appropriate — other factors will guide the recommendation
Yes — perimenopausal or menopausalTirzepatide's GIP component addresses the increased insulin resistance that accompanies estrogen decline — stronger clinical rationale for women in this phase
Yes — woman over 35 with weight gain around the midsectionAbdominal fat shift is often driven by insulin resistance — tirzepatide's dual mechanism targets this specifically
No — this doesn't apply to meOther clinical factors will guide the recommendation
Very important — I need the most affordable optionCompounded semaglutide from ~$99/mo vs tirzepatide from ~$149/mo. Semaglutide still produces 15% average weight loss.
Somewhat — I'm cost-conscious but open to better resultsThe $50/month difference may be worth it if clinical factors favor tirzepatide
Not a major factor — I want the best resultsTirzepatide's superior outcomes justify the higher cost for patients who can absorb it
Clinical note: This quiz is based on published GLP-1 clinical trial data and standard prescribing guidelines. It provides general guidance — not a medical recommendation. Your physician will assess your complete health picture before prescribing.
Advertiser Disclosure: FuturWeightLoss.com receives compensation when you click links.